144 related articles for article (PubMed ID: 29554381)
1. Letter to the Editor: Ranibizumab 0.3 mg for Persistent Diabetic Macular Edema After Recent, Frequent, and Chronic Bevacizumab: The ROTATE Trial.
Călugăru D; Călugăru M
Ophthalmic Surg Lasers Imaging Retina; 2018 Mar; 49(3):160. PubMed ID: 29554381
[No Abstract] [Full Text] [Related]
2. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
[TBL] [Abstract][Full Text] [Related]
3. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
Shah CP; Heier JS
Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
[TBL] [Abstract][Full Text] [Related]
4. Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema.
Payne JF; Clark WL; Bruce BB; Wykoff CC; Brown DM; Menke BM; Iverson SM; Allen KF; Boyer DS;
Ophthalmology; 2018 Aug; 125(8):1304-1306. PubMed ID: 29729809
[No Abstract] [Full Text] [Related]
5. Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema.
Antoszyk AN; Tarnowski KW; Basu K; Ehrlich JS; Haskova Z
Ophthalmol Retina; 2020 Oct; 4(10):1034-1036. PubMed ID: 32512056
[No Abstract] [Full Text] [Related]
6. Association of Circulating Markers With Outcome Parameters in the Bevacizumab and Ranibizumab in Diabetic Macular Edema Trial.
Fickweiler W; Klaassen I; Vogels IM; Hooymans JM; Wolffenbuttel BH; Los LI; Schlingemann RO;
Invest Ophthalmol Vis Sci; 2016 Nov; 57(14):6234-6241. PubMed ID: 27842163
[TBL] [Abstract][Full Text] [Related]
7. TREATMENT PATTERNS AND 2-YEAR VISION OUTCOMES WITH BEVACIZUMAB IN DIABETIC MACULAR EDEMA: An Analysis From a Large U.S. Integrated Health Care System.
Fong DS; Luong TQ; Contreras R; Jimenez JJ; Custis PH; Patel V; Campbell JH
Retina; 2018 Sep; 38(9):1830-1838. PubMed ID: 28796143
[TBL] [Abstract][Full Text] [Related]
8. Dexamethasone and Anti-VEGF Combination Therapy for the Treatment of Diabetic Macular Edema.
Al-Khersan H; Hariprasad SM; Salehi-Had H
Ophthalmic Surg Lasers Imaging Retina; 2019 Jan; 50(1):4-7. PubMed ID: 30640389
[No Abstract] [Full Text] [Related]
9. Frequency of Bevacizumab and Ranibizumab Injections for Diabetic Macular Edema in Medicare Beneficiaries.
Wu CM; Wu AM; Greenberg PB; Yu F; Lum F; Coleman AL
Ophthalmic Surg Lasers Imaging Retina; 2018 Apr; 49(4):241-244. PubMed ID: 29664980
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
Chen YY; Chang PY; Wang JK
Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
[TBL] [Abstract][Full Text] [Related]
11. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
[TBL] [Abstract][Full Text] [Related]
12. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab.
Ashraf M; Souka AA; ElKayal H
Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):230-236. PubMed ID: 28297035
[TBL] [Abstract][Full Text] [Related]
13. Real-World Results of Intravitreal Ranibizumab, Bevacizumab, or Triamcinolone for Diabetic Macular Edema.
Koç İ; Kadayıfçılar S; Eldem B
Ophthalmologica; 2018; 239(2-3):85-93. PubMed ID: 29050009
[TBL] [Abstract][Full Text] [Related]
14. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
[TBL] [Abstract][Full Text] [Related]
15. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
[TBL] [Abstract][Full Text] [Related]
16. The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endothelium in the treatment of diabetic macular edema.
Guzel H; Bakbak B; Koylu MT; Gonul S; Ozturk B; Gedik S
Cutan Ocul Toxicol; 2017 Mar; 36(1):5-8. PubMed ID: 26911396
[TBL] [Abstract][Full Text] [Related]
17. Visual outcomes following anti-VEGF therapy in patients with DME.
Panigrahi PK; Patro M
Indian J Ophthalmol; 2024 Jul; 72(Suppl 4):S718. PubMed ID: 38953138
[No Abstract] [Full Text] [Related]
18. INVICTUS: intravitreal anti-VEGF and dexamethasone implant comparison for the treatment of diabetic macular edema: a 6 months follow-up Study.
Comet A; Gascon P; Sauvan L; Donnadieu B; Matonti F
Acta Ophthalmol; 2019 Sep; 97(6):e937-e938. PubMed ID: 30741468
[No Abstract] [Full Text] [Related]
19. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.
Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S
Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550
[TBL] [Abstract][Full Text] [Related]
20. VEGF inhibitors for AMD and diabetic macular edema.
Med Lett Drugs Ther; 2015 Mar; 57(1464):41-2. PubMed ID: 25758545
[No Abstract] [Full Text] [Related]
[Next] [New Search]
